Aurobindo Pharma revenue surged in Q2 FY27, with profits up 32.5%. Discover the key factors behind this remarkable growth.
ABBV Q3 earnings: Is it the best time to invest?
ABBV Q3 earnings show strong performance, raising EPS outlook for 2026. Discover what this means for investors now.
